Evidence map›Paper›PMID 39575651›Full record

ArticleClinical and translational science2024

What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?

Julia Kopanz, Bart Lagerwaard, Magdalena Beran, Jorien Veldwijk, Julia K Mader, Tina Pöttler, Dietrich Tews, Diederick E Grobbee, Mira G P Zuidgeest, Trials@Home consortium

Abstract read
In one paragraph

Article in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julia KopanzJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0003-4082-0807
Bart LagerwaardJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0001-8558-2385
Magdalena BeranCardiovascular Research Institute Maastricht (CARIM), Department of Internal Medicine, Maastricht University, Maastricht, the Netherlands.ORCID https://orcid.org/0000-0002-9950-5759
Jorien VeldwijkErasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0003-4822-5068
Julia K MaderDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0001-7854-4233
Tina PöttlerDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0009-0005-0266-0760
Dietrich TewsMVZ Diabeteszentrum Dr. Tews GmbH, Gelnhausen, Germany.ORCID https://orcid.org/0000-0002-8548-1709
Diederick E GrobbeeJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0003-4472-4468
Mira G P ZuidgeestJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0003-1463-8243
Trials@Home consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Decentralized clinical trials (DCTs), in which all or part of the trial activities are moved to the participants' immediate surroundings, promise to improve trial conduct. However, no evidence is available on what motivates people to participate in DCTs. Our aim was to determine the drivers and perceptions for participation in clinical trials with different decentralization levels in persons with type 2 diabetes mellitus. Five focus groups were conducted utilizing the nominal group technique in the Netherlands (n = 1), Germany (n = 1), and Austria (n = 3) with four to six participants per group. The focus groups were analyzed using thematic analysis. Of the 26 participants (10 females, median age: 66 years [IQR: 62-72]) 42% had previously participated in a trial, and almost all had internet access at home (96%). A total of seven main themes regarding participation in clinical trials (location, time investment, contact with healthcare professionals (HCPs), digital technologies, data collection, perceived risk, and motivation) were identified, of which a total of 20 drivers emerged. Perceptions regarding trial participation differed widely among participants, and individual preferences influenced which drivers were considered more important by participants. Flexibility of location and time spent on the trial were identified as the most motivating factors for participation in DCTs. Some drivers, such as digital infrastructure, digital literacy, home visits, personal interaction, and relationship with HCPs were perceived as both enablers and barriers, depending on personal preferences. However, most of the potential barriers regarding DCTs may be resolved by addressing them in the design of future DCTs.

Indexed as

Clinical Trials as TopicDiabetes Mellitus, Type 2Focus GroupsMotivationAgedAustriaFemaleGermanyHumansMaleMiddle AgedNetherlandsPatient Participation

Identifiers

PMID39575651
PMCPMC11582682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.